Most Popular
-
1
Jung's paternity reveal exposes where Korea stands on extramarital babies
-
2
Samsung entangled in legal risks amid calls for drastic reform
-
3
Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
-
4
[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
-
5
Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
-
6
[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle
![[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050043_0.jpg&u=20241126145342)
-
7
Prosecutors seek 5-year prison term for Samsung chief in merger retrial
-
8
UN talks on plastic pollution treaty begin with grim outlook
-
9
[More than APT] Changing the value of 'home'
![[More than APT] Changing the value of 'home'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050076_0.jpg&u=20241126170025)
-
10
K-pop fandoms wield growing influence over industry decisions
![[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050043_0.jpg&u=20241126145342)
![[More than APT] Changing the value of 'home'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050076_0.jpg&u=20241126170025)
GeneOne Life Science wins EMA nod for phase 2 clinical study of COVID-19 treatment
By Shim Woo-hyunPublished : Nov. 1, 2021 - 16:33
GeneOne Life Science’s investigational oral drug for COVID-19 has received regulatory approvals from the European Medicines Agency and Bulgaria to conduct a phase 2 clinical trial in Bulgaria, the Korean biotech firm said Monday.
The Balkan nation is among the five regions where GeneOne Life Science plans to conduct phase 2 studies of GLS-1027. It is also the last of the five to give the company a go-ahead. The four others are the US, South Korea, Puerto Rico and North Macedonia.
GeneOne Life Science plans to confirm GLS-1027’s therapeutic effect on a total of 132 patients infected with COVID-19 and its variants through safety and efficacy tests.
GLS-1027 is being developed as an oral pill that could suppress severe pneumonia caused by COVID-19 infection.
In animal tests, it showed therapeutic effects on pneumonia caused by the coronavirus.
GeneOne Life Science hopes that the drug candidate could also be applied to treat other autoimmune diseases.
